domingo, 2 de junio de 2019

Advocates and FDA try to blaze trail to regulatory compromise on CBD

Advocates and FDA try to blaze trail to regulatory compromise on CBD

Daily Recap

At first-ever public hearing on CBD, advocates and FDA try to blaze trail to regulatory compromise

By NICHOLAS FLORKO


JEREMY REHM/AP
The meeting on Friday was the public kickoff of the FDA’s quest to sketch a clear framework to regulate CBD, or cannabidiol, products.

No hay comentarios: